BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day everyone. Welcome to B1 Q2 2025 earnings call webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks there will be a question and answer session. At this time I would like to turn the call over to the company. Hello and welcome. Thanks for joining us today. I'm Dan Mallor head of investor relations at B1 Medicines. Before we begin please note that you can find additional materials including a replay of today's webcast and presentation on the investor relations section of our website .B1Medicines.com. I would like to remind all participants that during this call we may make forward-looking statements regarding among other things the company's future prospects business strategy. Actual results may differ materially from those indicated and the forward statements has resulted various factors including those risks discussed in our most recent periodic report filed with the SEC. Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation. Reconciliation between gap and non-gap financial measures discussed on this call provided in the appendix to our presentation which is posted to our investor relations website along with our instruments. All information in this presentation is as of the date of this presentation we undertake no duty to update such information unless required by law. Now turning to today's call as outlined on slide three. John Euler our co-founder chairman and CEO will provide a business update. Aaron Rosenberg our CFO will provide an update on our second quarter financial results and financial guidance and Lai Wang our global head of R&D will discuss our R&D and pipeline progress. We will then open the call to questions I'll now pass...